Hosted on MSN2mon
MSD makes obesity play in up to $2bn deal for Hansoh’s GLP-1RA asset
Merck & Co (MSD) has entered an exclusive global licence agreement with China-based Hansoh Pharma for a preclinical ... commercialise the candidate named HS-10535. Hansoh is also in line for ...
Hosted on MSN2mon
Pharma Stock Roundup: PFE's 2025 Outlook, MRK & ABBV's M&A Deals
HS-10535, from Chinese biotech Hansoh Pharma. For the exclusive deal, Merck will make an upfront payment of $112 million to Hansoh Pharma, with the latter also being entitled to receive up to $1.9 ...
pharmaphorum2mon
MSD makes its obesity move with $2bn Hansoh deal
MSD has been rumoured to be considering a takeover of Viking Therapeutics in order to get a horse in the obesity therapy race, but chose instead to back a runner from China's Hansoh Pharma.
Yahoo Finance15d
Wall Street Thinks This Weight Loss Drug Stock Could More Than 3X Over the Next 12 Months -- and It's Not Eli Lilly or Novo Nordisk
Also, Viking was seen by some as a potential acquisition target for Merck. However, Merck announced in December 2024 it was licensing Hansoh Pharma's obesity drug HS-10535. This move added a new (and ...
Yahoo Finance25d
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever.
The company has penned a deal to develop a potential GLP-1 weight loss therapy, HS-10535, with China-based Hansoh Pharma. It signed a similar licensing deal with LaNova Medicines for the ...
Nasdaq14d
Wall Street Thinks This Weight Loss Drug Stock Could More Than 3X Over the Next 12 Months -- and It's Not Eli Lilly or Novo Nordisk
However, Merck announced in December 2024 it was licensing Hansoh Pharma's obesity drug HS-10535. This move added a new (and potentially formidable) competitor for Viking and greatly reduced the ...